SABCS 2024: Updates From Clinical Trials of Elacestrant for ER+/HER2– Metastatic Breast Cancer From SABCS 2024
Hope S. Rugo, MD, FASCO, provides comprehensive guidance on elacestrant’s clinical efficacy in ER+/HER2– metastatic breast cancer, including its performance in the EMERALD trial, ongoing combination studies (ELEVATE and ELECTRA), and the critical role of molecular testing and ctDNA analysis in treatment planning, while noting these data from SABCS 2024.
EP. 1: Lessons From EMERALD: Single-Agent Elacestrant for HR+/HER2– Metastatic Breast Cancer
December 11th 2024Hope S. Rugo, MD, FASCO, discusses how elacestrant, an oral selective estrogen receptor degrader, demonstrated superior progression-free survival compared with standard endocrine therapy in patients with ER+/HER2– metastatic breast cancer (MBC) who had previously received CDK4/6 inhibitors in the phase 3 EMERALD trial.
Watch
EP. 2: Rationale for Combining Elacestrant With Targeted Agents
December 11th 2024A panelist discusses how combining elacestrant with targeted therapies like CDK4/6 inhibitors or PI3K inhibitors could potentially enhance its efficacy and overcome resistance mechanisms in ER+/HER2– MBC treatment.
Watch
